Table 1.

Number of deaths and patients at risk for every consecutive 2-month period as extracted from digitized survival curves (see appendix for details)

Study 1				Study 2				Study 3				Study 4				Study 5				Study 6				Study 7
Lee et al., 2010				Chang et al. 2006				Kim et al., 2008				Maruyama et al., 2008				Hanna et al., 2004				Cufer et al., 2006				Shepherd et al., 2000
Gefitinib		Docetaxel		BSC		Gefitinib		Gefitinib		Docetaxel		Gefitinib		Docetaxel		Pemtrexed		Docetaxel		Gefitinib		Docetaxel		BSC		Docetaxel
r	n	r	n	r	N	r	n	r	n	r	n	r	n	r	n	r	n	r	n	r	n	r	n	r	n	r	n
7	81	9	76	22	107	34	235	98	723	73	710	18	245	9	244	27	283	33	288	11	68	14	73	17	222	49	441
5	74	4	67	24	85	35	201	104	625	109	637	30	226	21	233	47	256	48	255	8	57	11	59	71	205	67	392
7	69	8	64	11	61	29	166	94	518	102	503	25	197	23	214	31	209	41	207	5	49	6	48	53	134	60	325
6	62	5	56	8	50	15	137	79	424	66	401	22	169	15	189	33	178	21	166	14	44	6	42	70	160	63	340
6	55	8	51	12	42	11	122	64	336	68	339	12	148	23	173	40	144	34	144	9	31	7	36	12	90	49	277
3	49	4	38	6	30	14	110	46	272	41	271	18	127	17	140	17	78	17	78	4	21	4	29	22	78	14	228
4	46	6	34	1	24	1	97	35	225	32	228	10	98	9	105	21	61	13	61	8	18					55	221
3	42	2	28					30	190	29	196	8	77	10	87	8	40	18	48							41	166
3	38	4	26					14	131	18	139	6	63	15	69	11	33	9	30							30	125
3	35	3	22					14	117	16	121	4	47	4	44			10	21
5	29	3	18					14	83	13	89	3	35	5	35
4	24	2	15					8	69	10	76	1	29	3	25
3	21	1	13					5	50	6	46	1	25	2	18
1	18	1	12					3	45	5	40	2	18	1	14
3	17	2	10					6	31	4	24			1	10
3	14	2	8							3	20
1	12